Nonnucleoside reverse transcriptase inhibitors (NNRTIs)

Human Immunodeficiency Virus Reverse Transcriptase: A Bench-to-Bedside Success

Volumn , Issue , 2013, Pages 123-139

  Das, Kalyan ^a   Arnold, Eddy ^a   Hughes, Stephen H ^b  

^a RUTGERS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84899477987     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7291-9_6     Document Type: Chapter

References (53)

1. Abbondanzieri EA, Bokinsky G, Rausch JW, Zhang JX, Le Grice SF, Zhuang X (2008) Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 453(7192):184-189
2. Ambrose Z, Julias JG, Boyer PL, Kewalramani VN, Hughes SH (2006) The level of reverse transcriptase (RT) in human immunodeficiency virus type 1 particles affects susceptibility to nonnucleoside RT inhibitors but not to lamivudine. J Virol 80(5):2578-2581
3. Armstrong KL, Lee TH, Essex M (2011) Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C. Antimicrob Agents Chemother 55(5):2146-2153
4. Arnold E, Das K, Ding J, Yadav PNS, Hsiou Y, Boyer PL, Hughes SH (1996) Targeting HIV reverse transcriptase for anti-AIDS drug design: Structural and biological considerations for chemotherapeutic strategies. Drug Design and Discovery 13(3-4):29-47
5. Barber AM, Hizi A, Maizel JV Jr, Hughes SH (1990) HIV-1 reverse transcriptase: structure predictions for the polymerase domain. AIDS Res Hum Retroviruses 6(9):1061-1072
6. Boyer PL, Ding J, Arnold E, Hughes SH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38(9):1909-1914
7. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K et al (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378(9787):229-237
8. Das K, Ding J, Hsiou Y, Clark AD Jr, Moereels H, Koymans L et al (1996) Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J Mol Biol 264(5):1085-1100
9. Das K, Clark AD Jr, Lewi PJ, Heeres J, De Jonge MR, Koymans LM et al (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47(10): 2550-2560
10. Das K, Lewi PJ, Hughes SH, Arnold E (2005) Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of nonnucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 88(2):209-231
11. Das K, Bauman JD, Clark AD Jr, Frenkel YV, Lewi PJ, Shatkin AJ et al (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci USA 105(5):1466-1471
12. Das K, Bauman JD, Rim AS, Dharia C, Clark AD Jr, Camarasa MJ et al (2011) Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket. J Med Chem 54(8):2727-2737
13. Das K, Martinez SE, Bauman JD, Arnold E (2012) HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat Struct Mol Biol 19(2):253-259
14. Deeks SG (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26(Suppl 1):S25-S33
15. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA et al (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 2(5):407-415
16. Farr SL, Nelson JA, Ng'ombe TJ, Kourtis AP, Chasela C, Johnson JA et al (2010) Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi. J Acquir Immune Defic Syndr 54(5):515-523
17. Ford N, Calmy A, Mofenson L (2011) Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 25(18):2301-2304
18. Gazzard B, Duvivier C, Zagler C, Castagna A, Hill A, van Delft Y et al (2011) Phase 2 doubleblind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS 25(18):2249-2258
19. Gopalakrishnan V, Benkovic S (1994) Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase. J Biol Chem 269(6):4110-4115
20. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C et al (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 39(8):1589-1600
21. Hsiou Y, Ding J, Das K, Clark AD Jr, Hughes SH, Arnold E (1996) Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4(7):853-860
22. Hsiou Y, Das K, Ding J, Clark AD Jr, Kleim JP, Rosner M et al (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol 284(2):313-323
23. Hsiou Y, Ding J, Das K, Clark AD Jr, Boyer PL, Lewi P et al (2001) The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 309(2):437-445
24. Huang H, Chopra R, Verdine GL, Harrison SC (1998) Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282(5394):1669-1675
25. Jacobo-Molina A, Ding J, Nanni RG, Clark AD Jr, Lu X, Tantillo C et al (1993) Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci USA 90(13):6320-6324
26. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J et al (2005) In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 48(6):1901-1909
27. Jilek BL, Zarr M, Sampah ME, Rabi SA, Bullen CK, Lai J et al (2012) A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med 18(3):446-451
28. Joly V, Descamps D, Peytavin G, Touati F, Mentre F, Duval X et al (2004) Evolution of human immunodeficiency virus type 1 (HIV-1) resistance mutations in nonnucleoside reverse transcriptase inhibitors (NNRTIs) in HIV-1-infected patients switched to antiretroviral therapy without NNRTIs. Antimicrob Agents Chemother 48(1):172-175
29. Julias JG, Ferris AL, Boyer PL, Hughes SH (2001) Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase. J Virol 75(14):6537-6546
30. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG et al (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105(21):7552-7557
31. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256(5065): 1783-1790
32. Lansdon EB, Samuel D, Lagpacan L, Brendza KM, White KL, Hung M et al (2010) Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J Mol Biol 397(4):967-978
33. Micek MA, Blanco AJ, Carlsson J, Beck IA, Dross S, Matunha L et al (2012) Effects of shortcourse zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. J Infect Dis 205(12):1811-1815
34. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M et al (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378(9787): 238-246
35. Palaniappan C, Fay PJ, Bambara RA (1995) Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase. J Biol Chem 270(9): 4861-4869
36. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J et al (2006) Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 103(18):7094-7099
37. Palmer S, Boltz VF, Chow JY, Martinson NA, McIntyre JA, Gray GE et al (2012) Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther 17(2):327-336
38. Pelemans H, Esnouf R, De Clercq E, Balzarini J (2000) Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. Mol Pharmacol 57(5):954-960
39. Ren J, Esnouf R, Hopkins A, Ross C, Jones Y, Stammers D et al (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3(9):915-926
40. Ren J, Esnouf RM, Hopkins AL, Stuart DI, Stammers DK (1999) Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies. J Med Chem 42(19):3845-3851
41. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK (2002) Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to nonnucleoside inhibitors. Proc Natl Acad Sci USA 99(22):14410-14415
42. Restle T, Muller B, Goody RS (1990) Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J Biol Chem 265(16): 8986-8988
43. Rittinger K, Divita G, Goody RS (1995) Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 92(17):8046-8049
44. Sarafianos SG, Das K, Tantillo C, Clark AD Jr, Ding J, Whitcomb JM et al (2001) Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J 20(6):1449-1461
45. Sarafianos SG, Clark AD Jr, Das K, Tuske S, Birktoft JJ, Ilankumaran P et al (2002) Structures of HIV-1 reverse transcriptase with pre-and post-translocation AZTMP-terminated DNA. EMBO J 21(23):6614-6624
46. Spence RA, Kati WM, Anderson KS, Johnson KA (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267(5200):988-993
47. Tachedjian G, Goff SP (2003) The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr Opin Investig Drugs 4(8):966-973
48. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP (2001) Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 98(13):7188-7193
49. Tachedjian G, Moore KL, Goff SP, Sluis-Cremer N (2005) Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. FEBS Lett 579(2):379-384
50. Tu X, Das K, Han Q, Bauman JD, Clark AD Jr, Hou X et al (2010) Structural basis of HIV-1 resistance to AZT by excision. Nat Struct Mol Biol 17(10):1202-1209
51. Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL et al (2004) Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol 11(5):469-474
52. Wang J, Bambara RA, Demeter LM, Dykes C (2010) Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol 84(18):9377-9389
53. Watts DH (2007) Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep 4(3):135-140